Abstract
Background. Neoadjuvant chemotherapy is the most accepted treatment for localized osteosarcoma. This has led to a great improvement in limb-sparing surgery and in disease-free survival. Patients with a good response to preoperative chemotherapy showed a higher disease-free survival rate. Current studies examine the possibility of patients whose limbs could be rescued with a poor necrosis and a reduction of the side effects related to aggressive treatments. Methods. Between September 1986 and December 1989, 164 patients entered the second neoadjuvant study conducted at the Rizzoli Institute, Bologna, Italy, for nonmetastatic osteosarcoma of the extremities. Preoperative chemotherapy consisted of two cycles of high-dose methotrexate intravenously (IV) followed by cisplatin intraarterially and doxorubicin IV. After surgery, patients classified as good responders (> 90% tumor necrosis) received three more cycles of these drugs, whereas poor responders (
| Original language | English |
|---|---|
| Pages (from-to) | 3227-3238 |
| Number of pages | 12 |
| Journal | Cancer |
| Volume | 72 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 1993 |
Fingerprint
Keywords
- limb salvage
- malignant bone tumors
- neoadjuvant chemotherapy
- osteosarcoma
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities : Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. / Bacci, G.; Picci, P.; Ferrari, S.; Ruggieri, P.; Casadei, R.; Tienghi, A.; Del Prever, A. B.; Gherlinzoni, F.; Mercuri, M.; Monti, C.
In: Cancer, Vol. 72, No. 11, 1993, p. 3227-3238.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities
T2 - Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin
AU - Bacci, G.
AU - Picci, P.
AU - Ferrari, S.
AU - Ruggieri, P.
AU - Casadei, R.
AU - Tienghi, A.
AU - Del Prever, A. B.
AU - Gherlinzoni, F.
AU - Mercuri, M.
AU - Monti, C.
PY - 1993
Y1 - 1993
N2 - Background. Neoadjuvant chemotherapy is the most accepted treatment for localized osteosarcoma. This has led to a great improvement in limb-sparing surgery and in disease-free survival. Patients with a good response to preoperative chemotherapy showed a higher disease-free survival rate. Current studies examine the possibility of patients whose limbs could be rescued with a poor necrosis and a reduction of the side effects related to aggressive treatments. Methods. Between September 1986 and December 1989, 164 patients entered the second neoadjuvant study conducted at the Rizzoli Institute, Bologna, Italy, for nonmetastatic osteosarcoma of the extremities. Preoperative chemotherapy consisted of two cycles of high-dose methotrexate intravenously (IV) followed by cisplatin intraarterially and doxorubicin IV. After surgery, patients classified as good responders (> 90% tumor necrosis) received three more cycles of these drugs, whereas poor responders (
AB - Background. Neoadjuvant chemotherapy is the most accepted treatment for localized osteosarcoma. This has led to a great improvement in limb-sparing surgery and in disease-free survival. Patients with a good response to preoperative chemotherapy showed a higher disease-free survival rate. Current studies examine the possibility of patients whose limbs could be rescued with a poor necrosis and a reduction of the side effects related to aggressive treatments. Methods. Between September 1986 and December 1989, 164 patients entered the second neoadjuvant study conducted at the Rizzoli Institute, Bologna, Italy, for nonmetastatic osteosarcoma of the extremities. Preoperative chemotherapy consisted of two cycles of high-dose methotrexate intravenously (IV) followed by cisplatin intraarterially and doxorubicin IV. After surgery, patients classified as good responders (> 90% tumor necrosis) received three more cycles of these drugs, whereas poor responders (
KW - limb salvage
KW - malignant bone tumors
KW - neoadjuvant chemotherapy
KW - osteosarcoma
UR - http://www.scopus.com/inward/record.url?scp=0027381042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027381042&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO;2-C
DO - 10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO;2-C
M3 - Article
C2 - 8242546
AN - SCOPUS:0027381042
VL - 72
SP - 3227
EP - 3238
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 11
ER -